Description
Myo-Inositol Trispyrophosphate (ITPP) research compound
Myo-Inositol Trispyrophosphate (ITPP) is a synthetic allosteric effector of haemoglobin that lowers its oxygen affinity and increases oxygen release to tissues.
Product details
| Compound | Myo-inositol trispyrophosphate (ITPP) |
|---|---|
| Class | Allosteric haemoglobin effector |
| Form | Powder; Liquid; Capsules; Tablets |
| Strength | 1g; 30ml/33mg per ml/1000mg; 100mg per capsule/60ct/6000mg; 100mg per capsule/30ct/3000mg; 50mg per capsule/60ct/3000mg; 50mg per capsule/30ct/1500mg; 20mg per tab/27ct/540mg; 20mg per tab/54ct/1080mg; 50mg per tab/27ct/1350mg; 50mg per tab/54ct/2700mg |
| Labelling | Compound name and strength on every container |
Select your format and strength from the options above.
What research has examined
- Haemoglobin oxygen release research.
- Hypoxia models: tumour research.
- Clinical research: early oncology studies.
Research interest does not establish a proven effect in humans.
Regulatory status
ITPP is not an approved medicine and is prohibited in sport by WADA. Supplied as a research chemical only.
Storage and handling
Keep the container tightly closed, at room temperature or cooler, away from moisture and light.
Independent literature: search PubMed for published studies.
Related research products
Pterostilbene (Dimethylresveratrol) · Phenibut FAA · L-Theanine · All nootropic powders
For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure or prevent any disease.
Reviews
There are no reviews yet.